and DONALD OLDS, Defendants. Plaintiff, Lauden Bisel ( Plaintiff ), by his undersigned attorneys, alleges upon personal knowledge with respect to himself, and information and belief based upon,
inter alia, the investigation of counsel as to all other allegations herein, as follows:
NATURE OF THE ACTION 1.This is an action brought by Plaintiff against Acasti Pharma, Inc. ( Acasti or the Company ), and the members of Acasti s board of directors (the Board or the Individual Defendants and together with Acasti, the Defendants ) for their violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 ( Exchange Act ), 15 U.S.C. §§ 78n(a) and 78t(a), and SEC Rule 14a-9, 17 C.F.R. § 240.14a-9, in connection with the proposed merger between Acasti Pharma U.S., Inc., a wholly-owned subsidiary of Acasti and Grace Therapeutics Inc. ( Grace ) (the Proposed Merger ).
Acasti Pharma unveils proposal to buy Grace Therapeutics and its portfolio of drug candidates in all-stock deal
Acasti will acquire Grace’s entire therapeutic pipeline consisting of three unique clinical stage and multiple preclinical stage assets, supported by an intellectual property portfolio of more than 40 granted and pending patents Both companies boards have approved the deal thus far, as have Grace stockholders
Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) has announced a definitive agreement to acquire Grace Therapeutics Inc, a privately-held biopharmaceutical company developing drug delivery technologies for the treatment of rare and orphan diseases.
The deal would have Acasti acquire Grace’s entire therapeutic pipeline consisting of three unique clinical stage and multiple preclinical stage assets, supported by an intellectual property portfolio of more than 40 granted and pending patents globally. Both companies boards have approved the deal thus far